evAde
evAde aims to develop a novel anti-fungal immunotherapy based on binding innate immune components to the fungal surface. Thus, the project presents a potential solution for a critical unmet need for new anti-fungal therapeutics with a novel mechanism of action that can overcome the limitations of current treatment options.
Project summary
Purpose
Developing a novel anti-fungal immunotherapy based on binding innate immune components to the fungal surface.
Host institution
Copenhagen University Hospital - Rigshospitalet
Funding pr. year
5,35M DKK
Duration
Three years
Expected outcome
Viable startup that can raise seed or Series A financing.
Project leaders
See who heads evAde on its mission to develop a novel anti-fungal immunotherapy based on binding innate immune components to the fungal surface.
“Life-threatening invasive fungal infections are becoming increasingly untreatable because of antimicrobial resistance. The evAde platform represents a paradigm shift—empowering the immune system with mechanisms that sidestep conventional resistance pathways.”
Peter Garred
Principal Investigator